PMC:7269710 / 8006-8585 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"120","span":{"begin":226,"end":244},"obj":"Gene"},{"id":"121","span":{"begin":32,"end":38},"obj":"Species"},{"id":"122","span":{"begin":321,"end":329},"obj":"Species"},{"id":"123","span":{"begin":338,"end":347},"obj":"Chemical"},{"id":"124","span":{"begin":362,"end":371},"obj":"Chemical"},{"id":"125","span":{"begin":54,"end":62},"obj":"Disease"}],"attributes":[{"id":"A120","pred":"tao:has_database_id","subj":"120","obj":"Gene:1401"},{"id":"A121","pred":"tao:has_database_id","subj":"121","obj":"Tax:9606"},{"id":"A122","pred":"tao:has_database_id","subj":"122","obj":"Tax:9606"},{"id":"A123","pred":"tao:has_database_id","subj":"123","obj":"MESH:D061466"},{"id":"A124","pred":"tao:has_database_id","subj":"124","obj":"MESH:D019438"},{"id":"A125","pred":"tao:has_database_id","subj":"125","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Clinical management\nWe isolated people with confirmed COVID-19 in individual negative-pressure rooms with anterooms. We did blood investigations including a complete blood count, renal and liver function tests, and amounts of C-reactive protein and lactate dehydrogenase. Treatment was mainly supportive; we started some patients on oral lopinavir (400 mg) with ritonavir (100 mg) twice daily. We obtained clinical data for chronic medical illnesses, physical examinations, laboratory and radiological results, and clinical progression and outcome from inpatient medical records."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T3","span":{"begin":124,"end":129},"obj":"Body_part"},{"id":"T4","span":{"begin":166,"end":171},"obj":"Body_part"},{"id":"T5","span":{"begin":189,"end":194},"obj":"Body_part"},{"id":"T6","span":{"begin":237,"end":244},"obj":"Body_part"}],"attributes":[{"id":"A3","pred":"fma_id","subj":"T3","obj":"http://purl.org/sig/ont/fma/fma9670"},{"id":"A4","pred":"fma_id","subj":"T4","obj":"http://purl.org/sig/ont/fma/fma9670"},{"id":"A5","pred":"fma_id","subj":"T5","obj":"http://purl.org/sig/ont/fma/fma7197"},{"id":"A6","pred":"fma_id","subj":"T6","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"Clinical management\nWe isolated people with confirmed COVID-19 in individual negative-pressure rooms with anterooms. We did blood investigations including a complete blood count, renal and liver function tests, and amounts of C-reactive protein and lactate dehydrogenase. Treatment was mainly supportive; we started some patients on oral lopinavir (400 mg) with ritonavir (100 mg) twice daily. We obtained clinical data for chronic medical illnesses, physical examinations, laboratory and radiological results, and clinical progression and outcome from inpatient medical records."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T1","span":{"begin":124,"end":129},"obj":"Body_part"},{"id":"T2","span":{"begin":166,"end":171},"obj":"Body_part"},{"id":"T3","span":{"begin":189,"end":194},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"A2","pred":"uberon_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"A3","pred":"uberon_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/UBERON_0002107"}],"text":"Clinical management\nWe isolated people with confirmed COVID-19 in individual negative-pressure rooms with anterooms. We did blood investigations including a complete blood count, renal and liver function tests, and amounts of C-reactive protein and lactate dehydrogenase. Treatment was mainly supportive; we started some patients on oral lopinavir (400 mg) with ritonavir (100 mg) twice daily. We obtained clinical data for chronic medical illnesses, physical examinations, laboratory and radiological results, and clinical progression and outcome from inpatient medical records."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T51","span":{"begin":54,"end":62},"obj":"Disease"}],"attributes":[{"id":"A51","pred":"mondo_id","subj":"T51","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Clinical management\nWe isolated people with confirmed COVID-19 in individual negative-pressure rooms with anterooms. We did blood investigations including a complete blood count, renal and liver function tests, and amounts of C-reactive protein and lactate dehydrogenase. Treatment was mainly supportive; we started some patients on oral lopinavir (400 mg) with ritonavir (100 mg) twice daily. We obtained clinical data for chronic medical illnesses, physical examinations, laboratory and radiological results, and clinical progression and outcome from inpatient medical records."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T41","span":{"begin":124,"end":129},"obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"T42","span":{"begin":124,"end":129},"obj":"http://www.ebi.ac.uk/efo/EFO_0000296"},{"id":"T43","span":{"begin":155,"end":156},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T44","span":{"begin":166,"end":171},"obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"T45","span":{"begin":166,"end":171},"obj":"http://www.ebi.ac.uk/efo/EFO_0000296"},{"id":"T46","span":{"begin":189,"end":194},"obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"T47","span":{"begin":189,"end":194},"obj":"http://www.ebi.ac.uk/efo/EFO_0000887"},{"id":"T48","span":{"begin":204,"end":209},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"}],"text":"Clinical management\nWe isolated people with confirmed COVID-19 in individual negative-pressure rooms with anterooms. We did blood investigations including a complete blood count, renal and liver function tests, and amounts of C-reactive protein and lactate dehydrogenase. Treatment was mainly supportive; we started some patients on oral lopinavir (400 mg) with ritonavir (100 mg) twice daily. We obtained clinical data for chronic medical illnesses, physical examinations, laboratory and radiological results, and clinical progression and outcome from inpatient medical records."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T5","span":{"begin":237,"end":244},"obj":"Chemical"},{"id":"T6","span":{"begin":249,"end":256},"obj":"Chemical"},{"id":"T7","span":{"begin":338,"end":347},"obj":"Chemical"},{"id":"T8","span":{"begin":362,"end":371},"obj":"Chemical"}],"attributes":[{"id":"A5","pred":"chebi_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A6","pred":"chebi_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/CHEBI_24996"},{"id":"A7","pred":"chebi_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A8","pred":"chebi_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"}],"text":"Clinical management\nWe isolated people with confirmed COVID-19 in individual negative-pressure rooms with anterooms. We did blood investigations including a complete blood count, renal and liver function tests, and amounts of C-reactive protein and lactate dehydrogenase. Treatment was mainly supportive; we started some patients on oral lopinavir (400 mg) with ritonavir (100 mg) twice daily. We obtained clinical data for chronic medical illnesses, physical examinations, laboratory and radiological results, and clinical progression and outcome from inpatient medical records."}

{"project":"LitCovid-sentences","denotations":[{"id":"T66","span":{"begin":0,"end":19},"obj":"Sentence"},{"id":"T67","span":{"begin":20,"end":116},"obj":"Sentence"},{"id":"T68","span":{"begin":117,"end":271},"obj":"Sentence"},{"id":"T69","span":{"begin":272,"end":393},"obj":"Sentence"},{"id":"T70","span":{"begin":394,"end":579},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Clinical management\nWe isolated people with confirmed COVID-19 in individual negative-pressure rooms with anterooms. We did blood investigations including a complete blood count, renal and liver function tests, and amounts of C-reactive protein and lactate dehydrogenase. Treatment was mainly supportive; we started some patients on oral lopinavir (400 mg) with ritonavir (100 mg) twice daily. We obtained clinical data for chronic medical illnesses, physical examinations, laboratory and radiological results, and clinical progression and outcome from inpatient medical records."}